Tilray Medical Supports Fibromyalgia Research with Positive Results: Effectiveness of Cannabinoid Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms Page 1

LISBON, Portugal, Sept. 9, 2024 (GLOBE NEWSWIRE) — Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, strengthening the therapeutic alliance between patients and healthcare providers to make informed, individualized health decisions, today announced a new scientific publication supported by Tilray Medical titled, Treatment for pain management and other fibromyalgia-associated symptoms: a case series (TOMAS). The study investigates the impact of cannabinoid treatments in real-world settings on patients with fibromyalgia (FM), under the guidance of healthcare providers.

The TOMAS study, consisting of patients with a mean age of 52, investigated the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study sheds light on the impact of cannabinoids on health outcomes, with a specific focus on pain, sleep, and quality of life.

With the guidance and supervision of medical cannabis, the study demonstrated improvements in pain scores, sleep quality, and overall quality of life for fibromyalgia patients. Additionally, there was a notable reduction in co-medications, suggesting that cannabinoids may be an effective and cost-efficient treatment option for this population. The results of this study provide valuable insights to the medical and scientific community regarding the use of cannabinoids in managing chronic pain and improving the quality of life for patients with fibromyalgia.

José Tempero, Tilray’s Chief Medical Officer, commented, “The findings from this study are encouraging and provide hope for fibromyalgia patients seeking effective treatments. At Tilray, we are committed to conducting extensive scientific research that ensures our treatments are evidence-based and can improve patient care. We believe these results represent an important step forward in furthering the understanding of the therapeutic potential of cannabinoids and their role in managing chronic pain.”

Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, said: “Tilray’s involvement in this study underscores our unwavering commitment to advancing medical research and unlocking the full therapeutic potential of medical cannabis. The TOMAS study and its positive results for patients with fibromyalgia highlight the potential of cannabinoids as a safe and effective treatment option for patients with chronic pain and associated symptoms. Tilray Medical remains committed to advancing the science of medical cannabis and empowering patients and healthcare providers with the knowledge they need to make informed decisions about their health.”

Diskutieren Sie über die entaltenen Werte